-
Global Neorecormon Market Forecast: Key Growth Drivers, Trends, And Opportunities From 2025 To 2034
12 Mar 2025 12:28 GMT
… of Growth in the Neorecormon Market?
Neorecormon plays a crucial role … medicine.
• Integration of digital health solutions for treatment management.
• Rising collaborations between pharmaceutical … com/report/neorecormon-global-market-report
Who …
-
Global Neorecormon Market Forecast 2025-2034: Analyzing Growth Drivers, Market Share, Segments, and Emerging Trends
06 Feb 2025 17:55 GMT
… personalized medicine models, integrating digital health technologies for better treatment management … and rising collaborations across pharmaceutical companies and healthcare providers … Key Players In The Neorecormon Market?
Neorecormon's journey is …
-
Human medicines European public assessment report (EPAR): NeoRecormon, epoetin beta, Date of authorisation: 16/07/1997, Revision: 34, Status: Authorised
22 Jul 2024 18:58 GMT
The types of side effects seen with NeoRecormon depend on the cause of the patient’s anaemia. The most common side effects (seen in between 1 and 10 patients in 100) are hypertension (high blood pressure), headache and thromboembolic events (formation of …
-
Roche partners with Entero Healthcare on nephrology medicines
18 Jun 2020 06:52 GMT
… to improve access to nephrology medicines.
Under this agreement, … nephrology drugs, Mycophenolate Mofetil (Cellcept), Valganciclovir (Valcyte), Epoetin Beta (NeoRecormon), and …
Or click on Free Trial to get 14 days … free trial.
What You' …
-
Roche Pharma India expands partnership with Cipla for key oncology medicines
18 Jun 2020 06:23 GMT
… to its key oncology medicines in India.
Roche … of its trademark oncology drugs - trastuzumab (Herclon), … improve access to nephrology medicines in India.
Under … drugs such as mycophenolate mofetil (Cellcept), valganciclovir (Valcyte), epoetin beta (NeoRecormon …
-
An economist’s perspective on abuse of dominance and killer acquisitions in the pharma industry
14 Aug 2024 12:58 GMT
… drugs, biosimilar drugs are ‘similar to’ the originator biological medicine … generic challenger, for treatment of opiate addiction … Portugal)
Roche
NeoRecormon and Aranesp, prescription pharmaceuticals restricted to … the companies offered remedies to ensure that …
-
Injectable Hematology Growth Factors Report 2024 - Evolution in Therapeutic Care - ResearchAndMarkets.com
13 Feb 2024 12:11 GMT
… of Biological Drugs
Product Manufacturers
…
Grastofil
Mircera
NeoRecormon
Neulasta
Neupogen
… Medice Arzneimittel
Mylan International
Novartis
Pfizer
Ratiopharm
Rentscler Biotechnologie …
Roche
Sandoz
Stada Arzneimittel AG
Teva Pharmaceuticals …